IS2337B - Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4 - Google Patents

Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4

Info

Publication number
IS2337B
IS2337B IS6009A IS6009A IS2337B IS 2337 B IS2337 B IS 2337B IS 6009 A IS6009 A IS 6009A IS 6009 A IS6009 A IS 6009A IS 2337 B IS2337 B IS 2337B
Authority
IS
Iceland
Prior art keywords
dihydroxyhept
methylsulfonyl
pyrimidin
fluorophenyl
isopropyl
Prior art date
Application number
IS6009A
Other languages
English (en)
Other versions
IS6009A (is
Inventor
Raza Ali
Stuart Pears John
George Hutchinson Howard
Schneck Dennis
Baba Takahiko
Touchi Akira
Yamaguchi Yoshitaka
Original Assignee
Astrazeneca Ab
Shionogi & Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2337(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Application filed by Astrazeneca Ab, Shionogi & Co. Ltd. filed Critical Astrazeneca Ab
Publication of IS6009A publication Critical patent/IS6009A/is
Publication of IS2337B publication Critical patent/IS2337B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IS6009A 1999-02-06 2001-07-17 Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4 IS2337B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
PCT/GB2000/000278 WO2000045817A1 (en) 1999-02-06 2000-02-01 Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4

Publications (2)

Publication Number Publication Date
IS6009A IS6009A (is) 2001-07-17
IS2337B true IS2337B (is) 2008-02-15

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6009A IS2337B (is) 1999-02-06 2001-07-17 Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4

Country Status (29)

Country Link
US (3) US6982157B1 (is)
EP (1) EP1185274B1 (is)
JP (2) JP2002536331A (is)
KR (2) KR20060117381A (is)
CN (1) CN1165310C (is)
AR (1) AR029333A1 (is)
AT (1) ATE282415T1 (is)
AU (1) AU767304B2 (is)
BR (1) BR0007999A (is)
CA (1) CA2358632C (is)
CZ (1) CZ301296B6 (is)
DE (1) DE60015965T2 (is)
EE (1) EE04929B1 (is)
EG (1) EG23858A (is)
ES (1) ES2232418T3 (is)
GB (1) GB0000710D0 (is)
HK (1) HK1041817A1 (is)
ID (1) ID30485A (is)
IL (1) IL144715A0 (is)
IS (1) IS2337B (is)
MX (1) MXPA01007905A (is)
MY (1) MY130606A (is)
NO (1) NO320745B1 (is)
NZ (1) NZ512982A (is)
PL (1) PL198034B1 (is)
PT (1) PT1185274E (is)
TR (1) TR200102228T2 (is)
TW (1) TWI282738B (is)
WO (1) WO2000045817A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
EP1680091B1 (en) 2003-10-10 2017-05-31 Veloxis Pharmaceuticals A/S A solid dosage form comprising a fibrate
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7642287B2 (en) 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
EP1948600B1 (en) 2005-07-05 2014-04-16 The President & Fellows Of Harvard College Liver targeted conjugates
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
AU2019285170A1 (en) * 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
RS63740B1 (sr) 2019-07-31 2022-12-30 Intas Pharmaceuticals Ltd Farmaceutski sastav koji se sastoji od inhibitora hmg-coa reduktaze i fenofibrata

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE59200802D1 (de) * 1991-07-02 1995-01-05 Benckiser Gmbh Joh A Zusammenfaltbare Vorratsflasche.
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
JP4738592B2 (ja) * 1997-10-31 2011-08-03 アーチ・デヴェロップメント・コーポレイション ５α−還元酵素活性を調節するための方法及び組成物

Also Published As

Publication number Publication date
MXPA01007905A (es) 2003-06-04
CA2358632C (en) 2008-10-28
AR029333A1 (es) 2003-06-25
HK1041817A1 (en) 2002-07-26
EP1185274B1 (en) 2004-11-17
NO20013811L (no) 2001-10-02
US6982157B1 (en) 2006-01-03
MY130606A (en) 2007-07-31
KR20060117381A (ko) 2006-11-16
CA2358632A1 (en) 2000-08-10
US20060040969A1 (en) 2006-02-23
NO320745B1 (no) 2006-01-23
IL144715A0 (en) 2002-06-30
ATE282415T1 (de) 2004-12-15
CZ20012844A3 (cs) 2001-11-14
PT1185274E (pt) 2005-03-31
JP2002536331A (ja) 2002-10-29
WO2000045817A1 (en) 2000-08-10
JP2007277267A (ja) 2007-10-25
GB0000710D0 (en) 2000-03-08
IS6009A (is) 2001-07-17
CN1338936A (zh) 2002-03-06
NO20013811D0 (no) 2001-08-03
AU2121800A (en) 2000-08-25
TR200102228T2 (tr) 2002-03-21
KR20010101790A (ko) 2001-11-14
PL364780A1 (en) 2004-12-13
AU767304B2 (en) 2003-11-06
ES2232418T3 (es) 2005-06-01
EG23858A (en) 2007-11-18
US20090042911A1 (en) 2009-02-12
PL198034B1 (pl) 2008-05-30
EE200100406A (et) 2002-10-15
EP1185274A1 (en) 2002-03-13
ID30485A (id) 2001-12-13
BR0007999A (pt) 2001-11-06
NZ512982A (en) 2003-08-29
DE60015965T2 (de) 2006-01-05
CN1165310C (zh) 2004-09-08
CZ301296B6 (cs) 2010-01-06
TWI282738B (en) 2007-06-21
EE04929B1 (et) 2007-12-17
DE60015965D1 (de) 2004-12-23

Similar Documents

Publication Publication Date Title
IS2820B (is) Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru
IS2337B (is) Lyfjasamsetning sem samanstendur af (E)-7-[4-(4 flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimidín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru og hindra, vaka eða hvarfefni af P450 samsætuensími 3A4
CA2313783A1 (en) Pharmaceutical compositions of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a salt thereof
NO20023853L (no) Krystallinske salter av 7-[4-(fluorfenyl)-6-isopropyl-2- [metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre
HK1092462A1 (en) Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4- (4-fluorophenyl) -6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin -5- yl] (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
HUP0104828A2 (hu) Kristályos bisz[ (E)-7-[4-(4-fluor-fenil)-6-izopropil-2-[metil-(metilszulfonil)-amino]-pirimidin-5-il]-(3R,5S)-3,5-dihidroxi-6-hepténsav]-kalciumsó, ezt tartalmazó készítmény és eljárás az előállításukra
TWI370817B (en) Novel crystalline form of bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[ methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt,and relevant manufacture process, pharmaceutical composition, and use
CA2429263A1 (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
HUP0104977A3 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
SI1185274T1 (en) Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
DK1185274T3 (da) Lægemiddelkombinationer omfattende (E) - 7 -[4- (4-fluorphenyl) - 6 - isopropyl-2 [methyl(methylsulfonyl)amino ]-pyrimidin-5-yl] (3R,5S) - 3,5-dihydroxyhept-6-ensyre og en inhibitor af, en inducer af eller et substrat for P450 isoenzym 3A4